FTRE vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
FTRE exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While valuation metrics like Price/Sales (0.32) and PEG (0.34) suggest the stock is deeply undervalued, this is offset by negative revenue growth (-5.20%), a negative ROE of -102.41%, and a current ratio below 1.0 (0.98), signaling liquidity risks. Despite a 'Buy' consensus from analysts with a target of $13.21, the combination of C-suite insider selling and a consistent failure to meet earnings estimates suggests a high-risk profile.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
FTRE vs LLY: Head-to-Head Comparison
This page compares Fortrea Holdings Inc. (FTRE) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.